OncoDxRx

OncoDxRx's Spectacular PGA Technology Besides providing dazzling gene-to-drug technology—the latest liquid biopsy craze—is digging into rich cell-free mRNA data sets and uncovering meaningful results Gene-to-drug is poised to become the “next big thing” in precision medicine. On the strength of new PGA technologies, it promises to elevate an ambitious concept—the matching and prediction of the best drug(s) at the patient’s and molecular levels. Although the concept has been around for decades, transformational technologies are taking it to new heights. Indeed, PGA technology promises to usher gene-to-drug into a bright new era. We use lots of fancy terms, but gene-to-drug still means predicting drug response from gene patterns or signatures. Why is PGA so powerful? According to OncoDxRx, it provides the ability to understand the relationship between gene signature and mechanism of action of drug. PGA is expected to be especially valuable as a means of broadening the coverage of tailored personalized diagnostics and therapeutics for those cancer patients currently excluded from precision medicine, i.e., no actionable mutation detected following current NCCN testing workup. A tumor is not a tumor is not a tumor. Each tumor has a profile that depends on the tumor’s location and what the tumor microenvironment is. The PGA technology enabled an analysis of the gene expression fingerprints that predict to be responsive to certain drug(s). More specifically, the technology allowed hundreds of existing anticancer drugs to be examined in a single analysis. OncoDxRx’s team was able to take patient’s blood, profile gene expression, and report out a list of most effective, effective and less effective drugs within 5 days. Moreover, the team can deconvolute which class of drugs were most likely to have an effect. PGA is impressive not just for the depth of its analyses, but for the breadth of its applications. We welcome investment, licensing and partnership! #technology #medicine #data #testing #cancer #oncology #liquidbiopsy #team #precisiononcology

“We’re now working to deploy PGA and OncoMRD technologies as part of the counter-cancer diagnostic capability for precision oncology. Trials with real-world patients have also proved particularly conclusive, confirming their clinical utilities as highly effective, cost-controlled theranostic solutions for frontline decision-making.” -- OncoDxRx. #opportunities #strategy #programming #design #team #research #data #health #development #collaboration #projects #testing #immunotherapy #cancer #technology #biotechnology #healthcare #medicine #oncology #precisionmedicine #liquidbiopsy #rna #dna #venturecapital #startup #immunooncology #tcells #innovation #growth #tech #lifesciences #biopharma #oncodxrx #genomics #NGS #CRISPR #gene #geneexpression #artificialintelligence #machinelearning #sequencing #NGS #cancerresearch #personalizedmedicine #targetedtherapy #PrecisionOncology #Therapy #earlydetection #MRD?

"We need to be able to control cancer, in other words, to detect, identify and disable its ecosystem. And this is a domain that's moving very, very fast. We need to be very active in this area because it's a key element." In the end, it's the innovation and adaptability that we've seen throughout precision medicine, that mobilizes our energy in terms of our own preparation—OncoDxRx. The crucial lessons learned throughout this period inspired the invention of revolutionary technologies—PGA—at OncoDxRx. The message is to adapt to the new realities on the cancer battlefield. #opportunities #strategy #programming #design #team #research #data #health #development #collaboration #projects #testing #immunotherapy #cancer #technology #biotechnology #healthcare #medicine #oncology #precisionmedicine #liquidbiopsy #rna #dna #venturecapital #startup #immunooncology #tcells #innovation #growth #tech #lifesciences #biopharma #oncodxrx #genomics #NGS #CRISPR #gene #geneexpression #artificialintelligence #machinelearning #sequencing #NGS #cancerresearch #personalizedmedicine #targetedtherapy #PrecisionOncology #Therapy #earlydetection #MRD?

“In order to face cancer threats over time and in potential multiple theaters, we must further increase our precision theranostic capabilities. For OncoDxRx, this means PGA and OncoMRD.” Whatever one thinks of its ramifications, the fact remains that OncoDxRx has proven itself to be an enduring precision theranostics player with the creation, production, and operational use of exclusive gene signature-powered technology for precision oncology. #opportunities #strategy #programming #design #team #research #data #health #development #collaboration #projects #testing #immunotherapy #cancer #technology #biotechnology #healthcare #medicine #oncology #precisionmedicine #liquidbiopsy #rna #dna #venturecapital #startup #immunooncology #tcells #innovation #growth #tech #lifesciences #biopharma #oncodxrx #genomics #NGS #CRISPR #gene #geneexpression #artificialintelligence #machinelearning #sequencing #NGS #cancerresearch #personalizedmedicine #targetedtherapy #PrecisionOncology #Therapy #earlydetection #MRD?

Both the successes and failures of precision medicine are a lesson learned for OncoDxRx. "We need to be able to control cancer, in other words, to detect, identify and disable its ecosystem. And this is a domain that's moving very, very fast. We need to be very active in this area because it's a key element," OncoDxRx said. In the end, it's the innovation and adaptability that we've seen throughout precision medicine, that mobilizes our energy in terms of our own preparation." —OncoDxRx. The crucial lessons learned throughout this period inspired the invention of revolutionary technologies—PGA and OncoMRD—at OncoDxRx. The message is to adapt to the new realities on the cancer battlefield. #opportunities #strategy #programming #design #team #research #data #health #development #collaboration #projects #testing #immunotherapy #cancer #technology #biotechnology #healthcare #medicine #oncology #precisionmedicine #liquidbiopsy #rna #dna #venturecapital #startup #immunooncology #tcells #innovation #growth #tech #lifesciences #biopharma #oncodxrx #genomics #NGS #CRISPR #gene #geneexpression #artificialintelligence #machinelearning #sequencing #NGS #cancerresearch #personalizedmedicine #targetedtherapy #PrecisionOncology #Therapy #earlydetection #MRD ?

New cancer threats demand new responses. New technical possibilities enable new solutions. A new set of OncoDxRx’s technologies and decision-making aids enable real-time precision theranostics for patients unresponsive to precision medicine. With precision Dx and Rx?transformations?now well underway, clinicians are seeing the many ways new technologies can enhance and optimize their operations. They are also facing?evolutionarily dynamic tumors?with?genetic alterations, immunoediting, immunosuppression, drug resistance and more. To seize the advantages of precision medicine while safely and successfully minimizing the new threats it creates, clinical theranostics will need to be faster, more effective and more interconnected. OncoDxRx can help. The?PGA and OncoMRD platforms are?comprehensive solutions that provides actionable options to help patients, as well as to test, report, decide and act, from labs to clinicians out on the front line. Built on a lab-ready testing platform architecture, both PGA and OncoMRD leverage patient-derived gene expression signature and digital data analytics. #opportunities #strategy #programming #design #team #research #data #health #development #collaboration #projects #testing #immunotherapy #cancer #technology #biotechnology #healthcare #medicine #oncology #precisionmedicine #liquidbiopsy #rna #dna #venturecapital #startup #immunooncology #tcells #innovation #growth #tech #lifesciences #biopharma #oncodxrx #genomics #NGS #CRISPR #gene #geneexpression #artificialintelligence #machinelearning #sequencing #NGS #cancerresearch #personalizedmedicine #targetedtherapy #PrecisionOncology #Therapy #earlydetection #MRD?

OncoDxRx’s PGA breakthrough highlights how liquid biopsy transcriptomic profiling can play a crucial role in personalizing cancer care. By understanding how different gene signatures influence treatment response, doctors can select the most effective therapies - potentially avoiding ineffective therapies and focusing on those most likely to help. While cancer treatments have traditionally followed a one-size-fits-all approach, where patients with the same type of cancer receive the same standard therapies, PGA underscores the importance of precision medicine, which tailors treatment based on a patient's unique gene expression pattern. A groundbreaking study by OncoDxRx?(https://lnkd.in/gvKNT9Gn) has uncovered how specific?gene expression signatures?influence cancer treatment outcomes - insights that could help doctors tailor treatments more effectively. Building on these insights, the team developed the one-of-its-kind PGA technology to predict the best drugs that patients with advanced cancer may respond to (via screening from a library of existing 700+ cancer drugs either approved, in clinical trials or investigational). #opportunities #strategy #programming #design #team #research #data #health #development #collaboration #projects #testing #immunotherapy #cancer #technology #biotechnology #healthcare #medicine #oncology #precisionmedicine #liquidbiopsy #rna #dna #venturecapital #startup #immunooncology #tcells #innovation #growth #tech #lifesciences #biopharma #oncodxrx #genomics #NGS #CRISPR #gene #geneexpression #artificialintelligence #machinelearning #sequencing #NGS #cancerresearch #personalizedmedicine #targetedtherapy #PrecisionOncology #Therapy #earlydetection #MRD

OncoMRD: OncoDxRx Now Has One of Best Technology for Monitoring Residual Disease The OncoMRD (Monitoring Residual Disease) technology uses a mix of biomarkers and gene expression signatures to detect and quantify residual tumor activity primarily for treatment efficacy monitoring but can also perform the key role for relapse risk and prognosis. The OncoMRD package is platform-agnostic and could be easily integrated on other instrument families in a regular molecular diagnostic laboratory. At the heart of OncoMRD is the patient-derived gene signature, which is coupled with data analysis capabilities. OncoMRD’s core strength lies in its ability to detect residual “tumor activity” beyond genetic mutations and pinpoint their operators by analyzing target gene expression spectrum, enabling real-time MRD situational awareness and early signal detection. This allows clinicians to quantify and respond to potential MRD positivity with increased accuracy. OncoMRD’s proprietary signal processing and analytical algorithms contribute to the system’s beyond-tumor-mutation nature, meaning it could detect overactive signals from both tumor and non-tumor microenvironment, which enhances detection sensitivity and specificity—a critical feature for MRD measurement in clinical settings. The OncoMRD system represents a state-of-the-art quantum?leap from the traditional MRD assays—the?ctDNA-based?whole genome/exome sequencing?tests in service. OncoMRD integrates sophisticated cancer type-specific biomarkers and patient-unique gene signatures for enhanced detection and tracking capabilities. It is armed with digital data analytics, capable of determining and quantifying MRD scores. This combination of in vitro testing and in silico computation allows the OncoMRD test to effectively make the accurate calls, providing a significant boost to MRD measures in neoadjuvant, adjuvant and surveillance scenarios. #opportunities #strategy #programming #design #team #research #data #health #development #collaboration #projects #testing #immunotherapy #cancer #technology #biotechnology #healthcare #medicine #oncology #precisionmedicine #liquidbiopsy #rna #dna #venturecapital #startup #immunooncology #tcells #innovation #growth #tech #lifesciences #biopharma #oncodxrx #genomics #NGS #CRISPR #gene #geneexpression #artificialintelligence #machinelearning #sequencing #NGS #cancerresearch #personalizedmedicine #targetedtherapy #PrecisionOncology #Therapy #earlydetection #MRD?

Patient-Derived Gene Expression Signatures Are Pioneering?Residual Tumor Monitoring OncoDxRx’s?OncoMRD (Monitoring Residual Disease) technology is one of the most advanced MRD assay in service today, designed to revolutionize tumor tracking by offering unmatched detection capabilities against residual tumor activity at extreme sensitivity. At the heart of OncoMRD’s advantage is its patient-unique gene expression signature, which allows it to capture signals from both tumor and non-tumor microenvironment. Unlike traditional MRD testing, which only detects tumor DNA mutations by whole genome/exome sequencing, the OncoMRD can measure “tumor activity” dynamically. This results in a significantly extended functional genomics spectrum, enabling it to detect, identify and track overactive genes at scopes well beyond those of conventional DNA-based MRD assays. OncoMRD’s?ability to sustain quick turnaround, high throughput, low cost, adapt to dynamic testing workflows, and easy implementation makes it a defining technology in the modern precision oncology landscape. As cancer threats evolve and tumor clonal evolution advances, the OncoMRD ensures that the labs carrying it remain at the forefront of counter-cancer superiority. OncoMRD represents a generational shift in residual disease monitoring technology, providing OncoDxRx with a crucial edge in assessing therapeutic efficacy, relapse risk and disease prognosis. #opportunities #strategy #programming #design #team #research #data #health #development #collaboration #projects #testing #immunotherapy #cancer #technology #biotechnology #healthcare #medicine #oncology #precisionmedicine #liquidbiopsy #rna #dna #venturecapital #startup #immunooncology #tcells #innovation #growth #tech #lifesciences #biopharma #oncodxrx #genomics #NGS #CRISPR #gene #geneexpression #artificialintelligence #machinelearning #sequencing #NGS #cancerresearch #personalizedmedicine #targetedtherapy #PrecisionOncology #Therapy #earlydetection #MRD?

To seize the advantages of precision medicine while safely and successfully minimizing the new threats it creates, clinical theranostics will need to be faster, more effective and more interconnected. OncoDxRx can help. The PGA and OncoMRD platforms are comprehensive solutions that provides actionable options to help patients, as well as to test, report, decide and act, from labs to clinicians out on the front line. #opportunities #strategy #programming #design #team #research #data #health #development #collaboration #projects #testing #immunotherapy #cancer #technology #biotechnology #healthcare #medicine #oncology #precisionmedicine #liquidbiopsy #rna #dna #venturecapital #startup #immunooncology #tcells #innovation #growth #tech #lifesciences #biopharma #oncodxrx #genomics #NGS #CRISPR #gene #geneexpression #artificialintelligence #machinelearning #sequencing #NGS #cancerresearch #personalizedmedicine #targetedtherapy #PrecisionOncology #Therapy #earlydetection #MRD?